nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—CYP1A1—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0167	0.0503	CbGpPWpGaD
Thiabendazole—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.0153	0.0463	CbGpPWpGaD
Thiabendazole—CYP1A1—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0148	0.0445	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.012	0.0361	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0106	0.0321	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00941	0.0284	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00763	0.023	CbGpPWpGaD
Thiabendazole—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.0067	0.0202	CbGpPWpGaD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00663	0.02	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen metabolism—NQO1—urinary bladder cancer	0.00644	0.0194	CbGpPWpGaD
Thiabendazole—Confusional state—Mitomycin—urinary bladder cancer	0.00604	0.00904	CcSEcCtD
Thiabendazole—Diarrhoea—Valrubicin—urinary bladder cancer	0.00595	0.0089	CcSEcCtD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00576	0.0174	CbGpPWpGaD
Thiabendazole—Dizziness—Valrubicin—urinary bladder cancer	0.00575	0.0086	CcSEcCtD
Thiabendazole—Hepatic failure—Gemcitabine—urinary bladder cancer	0.00574	0.00858	CcSEcCtD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00573	0.0173	CbGpPWpGaD
Thiabendazole—Anorexia—Mitomycin—urinary bladder cancer	0.00571	0.00854	CcSEcCtD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00566	0.0171	CbGpPWpGaD
Thiabendazole—Vomiting—Valrubicin—urinary bladder cancer	0.00553	0.00827	CcSEcCtD
Thiabendazole—Rash—Valrubicin—urinary bladder cancer	0.00548	0.0082	CcSEcCtD
Thiabendazole—Dermatitis—Valrubicin—urinary bladder cancer	0.00548	0.00819	CcSEcCtD
Thiabendazole—Headache—Valrubicin—urinary bladder cancer	0.00545	0.00815	CcSEcCtD
Thiabendazole—Somnolence—Mitomycin—urinary bladder cancer	0.00532	0.00797	CcSEcCtD
Thiabendazole—Decreased appetite—Mitomycin—urinary bladder cancer	0.00521	0.00779	CcSEcCtD
Thiabendazole—Nausea—Valrubicin—urinary bladder cancer	0.00516	0.00773	CcSEcCtD
Thiabendazole—Fatigue—Mitomycin—urinary bladder cancer	0.00516	0.00773	CcSEcCtD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.00503	0.0152	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00494	0.0149	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00494	0.00739	CcSEcCtD
Thiabendazole—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.00478	0.00715	CcSEcCtD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00465	0.014	CbGpPWpGaD
Thiabendazole—Jaundice—Thiotepa—urinary bladder cancer	0.0046	0.00689	CcSEcCtD
Thiabendazole—Haematuria—Thiotepa—urinary bladder cancer	0.0045	0.00674	CcSEcCtD
Thiabendazole—Asthenia—Mitomycin—urinary bladder cancer	0.0043	0.00643	CcSEcCtD
Thiabendazole—CYP1A1—Oxidative Stress—NQO1—urinary bladder cancer	0.00428	0.0129	CbGpPWpGaD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00423	0.0128	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.00411	0.0124	CbGpPWpGaD
Thiabendazole—Diarrhoea—Mitomycin—urinary bladder cancer	0.0041	0.00613	CcSEcCtD
Thiabendazole—Liver injury—Epirubicin—urinary bladder cancer	0.00404	0.00604	CcSEcCtD
Thiabendazole—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00402	0.00601	CcSEcCtD
Thiabendazole—Dizziness—Mitomycin—urinary bladder cancer	0.00396	0.00593	CcSEcCtD
Thiabendazole—Tinnitus—Thiotepa—urinary bladder cancer	0.00395	0.00591	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00394	0.00589	CcSEcCtD
Thiabendazole—Vomiting—Mitomycin—urinary bladder cancer	0.00381	0.0057	CcSEcCtD
Thiabendazole—Chills—Thiotepa—urinary bladder cancer	0.0038	0.00569	CcSEcCtD
Thiabendazole—Haematuria—Gemcitabine—urinary bladder cancer	0.00379	0.00567	CcSEcCtD
Thiabendazole—Rash—Mitomycin—urinary bladder cancer	0.00378	0.00565	CcSEcCtD
Thiabendazole—Dermatitis—Mitomycin—urinary bladder cancer	0.00377	0.00565	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.00377	0.0114	CbGpPWpGaD
Thiabendazole—Headache—Mitomycin—urinary bladder cancer	0.00375	0.00561	CcSEcCtD
Thiabendazole—Liver injury—Doxorubicin—urinary bladder cancer	0.00374	0.00559	CcSEcCtD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00366	0.011	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00361	0.0109	CbGpPWpGaD
Thiabendazole—Nausea—Mitomycin—urinary bladder cancer	0.00356	0.00532	CcSEcCtD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00353	0.0106	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.00349	0.00522	CcSEcCtD
Thiabendazole—Vision blurred—Thiotepa—urinary bladder cancer	0.00348	0.0052	CcSEcCtD
Thiabendazole—Coordination abnormal—Epirubicin—urinary bladder cancer	0.00346	0.00518	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00345	0.0104	CbGpPWpGaD
Thiabendazole—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.0034	0.00509	CcSEcCtD
Thiabendazole—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00337	0.00505	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00336	0.00503	CcSEcCtD
Thiabendazole—Jaundice—Etoposide—urinary bladder cancer	0.00331	0.00495	CcSEcCtD
Thiabendazole—Leukopenia—Thiotepa—urinary bladder cancer	0.0033	0.00494	CcSEcCtD
Thiabendazole—CYP1A1—Oxidative Stress—SOD2—urinary bladder cancer	0.00329	0.00993	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.00327	0.00985	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.00327	0.00985	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.00321	0.00967	CbGpPWpGaD
Thiabendazole—Visual impairment—Cisplatin—urinary bladder cancer	0.0032	0.00479	CcSEcCtD
Thiabendazole—Coordination abnormal—Doxorubicin—urinary bladder cancer	0.0032	0.00479	CcSEcCtD
Thiabendazole—Chills—Gemcitabine—urinary bladder cancer	0.0032	0.00479	CcSEcCtD
Thiabendazole—Convulsion—Thiotepa—urinary bladder cancer	0.0032	0.00478	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00316	0.00954	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00315	0.00949	CbGpPWpGaD
Thiabendazole—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.00315	0.00471	CcSEcCtD
Thiabendazole—CYP1A1—Oxidative Stress—GPX1—urinary bladder cancer	0.00314	0.00947	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00312	0.00941	CbGpPWpGaD
Thiabendazole—Tinnitus—Cisplatin—urinary bladder cancer	0.0031	0.00464	CcSEcCtD
Thiabendazole—Lymphadenopathy—Methotrexate—urinary bladder cancer	0.00309	0.00462	CcSEcCtD
Thiabendazole—Flushing—Cisplatin—urinary bladder cancer	0.00309	0.00462	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00304	0.00917	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00304	0.00917	CbGpPWpGaD
Thiabendazole—Confusional state—Thiotepa—urinary bladder cancer	0.00304	0.00454	CcSEcCtD
Thiabendazole—Hypoaesthesia—Etoposide—urinary bladder cancer	0.00303	0.00453	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—GSTO2—urinary bladder cancer	0.003	0.00904	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—NAT1—urinary bladder cancer	0.003	0.00904	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00299	0.00901	CbGpPWpGaD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00296	0.00894	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00296	0.00892	CbGpPWpGaD
Thiabendazole—Hepatic failure—Methotrexate—urinary bladder cancer	0.00293	0.00439	CcSEcCtD
Thiabendazole—Lymphadenopathy—Epirubicin—urinary bladder cancer	0.00289	0.00433	CcSEcCtD
Thiabendazole—Erythema multiforme—Etoposide—urinary bladder cancer	0.00288	0.00431	CcSEcCtD
Thiabendazole—Vision blurred—Fluorouracil—urinary bladder cancer	0.00288	0.0043	CcSEcCtD
Thiabendazole—Anorexia—Thiotepa—urinary bladder cancer	0.00287	0.0043	CcSEcCtD
Thiabendazole—Flushing—Etoposide—urinary bladder cancer	0.00283	0.00423	CcSEcCtD
Thiabendazole—Leukopenia—Gemcitabine—urinary bladder cancer	0.00278	0.00416	CcSEcCtD
Thiabendazole—Hepatic failure—Epirubicin—urinary bladder cancer	0.00275	0.00411	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00274	0.00827	CbGpPWpGaD
Thiabendazole—Chills—Etoposide—urinary bladder cancer	0.00273	0.00409	CcSEcCtD
Thiabendazole—Leukopenia—Fluorouracil—urinary bladder cancer	0.00273	0.00409	CcSEcCtD
Thiabendazole—Vision blurred—Cisplatin—urinary bladder cancer	0.00273	0.00408	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.0027	0.00816	CbGpPWpGaD
Thiabendazole—Somnolence—Thiotepa—urinary bladder cancer	0.00268	0.00401	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—urinary bladder cancer	0.00268	0.004	CcSEcCtD
Thiabendazole—Dyspepsia—Thiotepa—urinary bladder cancer	0.00265	0.00397	CcSEcCtD
Thiabendazole—Convulsion—Fluorouracil—urinary bladder cancer	0.00264	0.00396	CcSEcCtD
Thiabendazole—Decreased appetite—Thiotepa—urinary bladder cancer	0.00262	0.00392	CcSEcCtD
Thiabendazole—Fatigue—Thiotepa—urinary bladder cancer	0.0026	0.00389	CcSEcCtD
Thiabendazole—Leukopenia—Cisplatin—urinary bladder cancer	0.00259	0.00388	CcSEcCtD
Thiabendazole—Hepatic failure—Doxorubicin—urinary bladder cancer	0.00254	0.0038	CcSEcCtD
Thiabendazole—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00253	0.00379	CcSEcCtD
Thiabendazole—Confusional state—Fluorouracil—urinary bladder cancer	0.00251	0.00376	CcSEcCtD
Thiabendazole—Convulsion—Cisplatin—urinary bladder cancer	0.00251	0.00375	CcSEcCtD
Thiabendazole—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00249	0.00373	CcSEcCtD
Thiabendazole—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00248	0.00371	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00247	0.00745	CbGpPWpGaD
Thiabendazole—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00246	0.00369	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00244	0.00734	CbGpPWpGaD
Thiabendazole—Anorexia—Gemcitabine—urinary bladder cancer	0.00242	0.00361	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.00241	0.00725	CbGpPWpGaD
Thiabendazole—Abdominal pain—Thiotepa—urinary bladder cancer	0.00238	0.00356	CcSEcCtD
Thiabendazole—Anorexia—Fluorouracil—urinary bladder cancer	0.00237	0.00355	CcSEcCtD
Thiabendazole—Leukopenia—Etoposide—urinary bladder cancer	0.00237	0.00355	CcSEcCtD
Thiabendazole—Hypotension—Gemcitabine—urinary bladder cancer	0.00237	0.00354	CcSEcCtD
Thiabendazole—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00236	0.00353	CcSEcCtD
Thiabendazole—Hypotension—Fluorouracil—urinary bladder cancer	0.00233	0.00348	CcSEcCtD
Thiabendazole—Convulsion—Etoposide—urinary bladder cancer	0.0023	0.00344	CcSEcCtD
Thiabendazole—Somnolence—Gemcitabine—urinary bladder cancer	0.00225	0.00337	CcSEcCtD
Thiabendazole—Anorexia—Cisplatin—urinary bladder cancer	0.00225	0.00337	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00225	0.00678	CbGpPWpGaD
Thiabendazole—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00222	0.00332	CcSEcCtD
Thiabendazole—Somnolence—Fluorouracil—urinary bladder cancer	0.00221	0.00331	CcSEcCtD
Thiabendazole—Hypotension—Cisplatin—urinary bladder cancer	0.00221	0.0033	CcSEcCtD
Thiabendazole—Decreased appetite—Gemcitabine—urinary bladder cancer	0.0022	0.0033	CcSEcCtD
Thiabendazole—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00219	0.00328	CcSEcCtD
Thiabendazole—Fatigue—Gemcitabine—urinary bladder cancer	0.00218	0.00327	CcSEcCtD
Thiabendazole—Confusional state—Etoposide—urinary bladder cancer	0.00218	0.00326	CcSEcCtD
Thiabendazole—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00217	0.00324	CcSEcCtD
Thiabendazole—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00216	0.00324	CcSEcCtD
Thiabendazole—Asthenia—Thiotepa—urinary bladder cancer	0.00216	0.00323	CcSEcCtD
Thiabendazole—Pruritus—Thiotepa—urinary bladder cancer	0.00213	0.00319	CcSEcCtD
Thiabendazole—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00209	0.00312	CcSEcCtD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00209	0.0063	CbGpPWpGaD
Thiabendazole—Anorexia—Etoposide—urinary bladder cancer	0.00206	0.00309	CcSEcCtD
Thiabendazole—Diarrhoea—Thiotepa—urinary bladder cancer	0.00206	0.00308	CcSEcCtD
Thiabendazole—Decreased appetite—Cisplatin—urinary bladder cancer	0.00205	0.00307	CcSEcCtD
Thiabendazole—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00205	0.00307	CcSEcCtD
Thiabendazole—Drowsiness—Methotrexate—urinary bladder cancer	0.00203	0.00304	CcSEcCtD
Thiabendazole—Hypotension—Etoposide—urinary bladder cancer	0.00202	0.00303	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.00202	0.00608	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00201	0.00301	CcSEcCtD
Thiabendazole—Dizziness—Thiotepa—urinary bladder cancer	0.00199	0.00298	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00199	0.006	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00195	0.00291	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00194	0.00585	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00194	0.00585	CbGpPWpGaD
Thiabendazole—Haematuria—Methotrexate—urinary bladder cancer	0.00194	0.0029	CcSEcCtD
Thiabendazole—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00192	0.00288	CcSEcCtD
Thiabendazole—Somnolence—Etoposide—urinary bladder cancer	0.00192	0.00288	CcSEcCtD
Thiabendazole—Vomiting—Thiotepa—urinary bladder cancer	0.00192	0.00287	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.00191	0.00576	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.00191	0.00576	CbGpPWpGaD
Thiabendazole—Drowsiness—Epirubicin—urinary bladder cancer	0.0019	0.00285	CcSEcCtD
Thiabendazole—Rash—Thiotepa—urinary bladder cancer	0.0019	0.00284	CcSEcCtD
Thiabendazole—Dermatitis—Thiotepa—urinary bladder cancer	0.0019	0.00284	CcSEcCtD
Thiabendazole—Headache—Thiotepa—urinary bladder cancer	0.00189	0.00282	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00189	0.00569	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00189	0.00282	CcSEcCtD
Thiabendazole—Decreased appetite—Etoposide—urinary bladder cancer	0.00188	0.00281	CcSEcCtD
Thiabendazole—Fatigue—Etoposide—urinary bladder cancer	0.00187	0.00279	CcSEcCtD
Thiabendazole—Jaundice—Epirubicin—urinary bladder cancer	0.00185	0.00277	CcSEcCtD
Thiabendazole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00184	0.00275	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.00183	0.00552	CbGpPWpGaD
Thiabendazole—Asthenia—Gemcitabine—urinary bladder cancer	0.00182	0.00272	CcSEcCtD
Thiabendazole—Haematuria—Epirubicin—urinary bladder cancer	0.00181	0.00271	CcSEcCtD
Thiabendazole—Pruritus—Gemcitabine—urinary bladder cancer	0.00179	0.00268	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.00179	0.0054	CbGpPWpGaD
Thiabendazole—Nausea—Thiotepa—urinary bladder cancer	0.00179	0.00268	CcSEcCtD
Thiabendazole—Feeling abnormal—Etoposide—urinary bladder cancer	0.00178	0.00267	CcSEcCtD
Thiabendazole—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00178	0.00266	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00177	0.00265	CcSEcCtD
Thiabendazole—Pruritus—Fluorouracil—urinary bladder cancer	0.00176	0.00264	CcSEcCtD
Thiabendazole—Drowsiness—Doxorubicin—urinary bladder cancer	0.00176	0.00263	CcSEcCtD
Thiabendazole—Visual impairment—Methotrexate—urinary bladder cancer	0.00176	0.00263	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.00175	0.00527	CbGpPWpGaD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00174	0.00261	CcSEcCtD
Thiabendazole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00174	0.0026	CcSEcCtD
Thiabendazole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00173	0.00259	CcSEcCtD
Thiabendazole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00172	0.00258	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00172	0.0052	CbGpPWpGaD
Thiabendazole—Jaundice—Doxorubicin—urinary bladder cancer	0.00172	0.00257	CcSEcCtD
Thiabendazole—Abdominal pain—Etoposide—urinary bladder cancer	0.00171	0.00256	CcSEcCtD
Thiabendazole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.0017	0.00255	CcSEcCtD
Thiabendazole—Tinnitus—Methotrexate—urinary bladder cancer	0.0017	0.00254	CcSEcCtD
Thiabendazole—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.0017	0.00254	CcSEcCtD
Thiabendazole—Asthenia—Cisplatin—urinary bladder cancer	0.00169	0.00254	CcSEcCtD
Thiabendazole—Haematuria—Doxorubicin—urinary bladder cancer	0.00168	0.00251	CcSEcCtD
Thiabendazole—Dizziness—Fluorouracil—urinary bladder cancer	0.00165	0.00247	CcSEcCtD
Thiabendazole—Visual impairment—Epirubicin—urinary bladder cancer	0.00165	0.00246	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—NAT2—urinary bladder cancer	0.00164	0.00495	CbGpPWpGaD
Thiabendazole—Chills—Methotrexate—urinary bladder cancer	0.00164	0.00245	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00162	0.00489	CbGpPWpGaD
Thiabendazole—Diarrhoea—Cisplatin—urinary bladder cancer	0.00162	0.00242	CcSEcCtD
Thiabendazole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00161	0.00242	CcSEcCtD
Thiabendazole—Vomiting—Gemcitabine—urinary bladder cancer	0.00161	0.00241	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.0016	0.00482	CbGpPWpGaD
Thiabendazole—Rash—Gemcitabine—urinary bladder cancer	0.0016	0.00239	CcSEcCtD
Thiabendazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.0016	0.00239	CcSEcCtD
Thiabendazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.00159	0.00239	CcSEcCtD
Thiabendazole—Tinnitus—Epirubicin—urinary bladder cancer	0.00159	0.00238	CcSEcCtD
Thiabendazole—Headache—Gemcitabine—urinary bladder cancer	0.00159	0.00238	CcSEcCtD
Thiabendazole—Flushing—Epirubicin—urinary bladder cancer	0.00158	0.00237	CcSEcCtD
Thiabendazole—Vomiting—Fluorouracil—urinary bladder cancer	0.00158	0.00237	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.00157	0.00475	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.00157	0.00235	CcSEcCtD
Thiabendazole—Rash—Fluorouracil—urinary bladder cancer	0.00157	0.00235	CcSEcCtD
Thiabendazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.00157	0.00235	CcSEcCtD
Thiabendazole—Headache—Fluorouracil—urinary bladder cancer	0.00156	0.00234	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00155	0.00468	CbGpPWpGaD
Thiabendazole—Asthenia—Etoposide—urinary bladder cancer	0.00155	0.00232	CcSEcCtD
Thiabendazole—Chills—Epirubicin—urinary bladder cancer	0.00153	0.00229	CcSEcCtD
Thiabendazole—Pruritus—Etoposide—urinary bladder cancer	0.00153	0.00229	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—urinary bladder cancer	0.00152	0.00228	CcSEcCtD
Thiabendazole—Nausea—Gemcitabine—urinary bladder cancer	0.00151	0.00225	CcSEcCtD
Thiabendazole—Vomiting—Cisplatin—urinary bladder cancer	0.0015	0.00225	CcSEcCtD
Thiabendazole—Vision blurred—Methotrexate—urinary bladder cancer	0.0015	0.00224	CcSEcCtD
Thiabendazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00149	0.00223	CcSEcCtD
Thiabendazole—Rash—Cisplatin—urinary bladder cancer	0.00149	0.00223	CcSEcCtD
Thiabendazole—Dermatitis—Cisplatin—urinary bladder cancer	0.00149	0.00223	CcSEcCtD
Thiabendazole—Diarrhoea—Etoposide—urinary bladder cancer	0.00148	0.00222	CcSEcCtD
Thiabendazole—Nausea—Fluorouracil—urinary bladder cancer	0.00148	0.00221	CcSEcCtD
Thiabendazole—Tinnitus—Doxorubicin—urinary bladder cancer	0.00147	0.0022	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—urinary bladder cancer	0.00147	0.00219	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.00143	0.00432	CbGpPWpGaD
Thiabendazole—Dizziness—Etoposide—urinary bladder cancer	0.00143	0.00214	CcSEcCtD
Thiabendazole—Leukopenia—Methotrexate—urinary bladder cancer	0.00142	0.00213	CcSEcCtD
Thiabendazole—Chills—Doxorubicin—urinary bladder cancer	0.00142	0.00212	CcSEcCtD
Thiabendazole—Nausea—Cisplatin—urinary bladder cancer	0.0014	0.0021	CcSEcCtD
Thiabendazole—Vision blurred—Epirubicin—urinary bladder cancer	0.0014	0.0021	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.00139	0.00419	CbGpPWpGaD
Thiabendazole—Convulsion—Methotrexate—urinary bladder cancer	0.00138	0.00206	CcSEcCtD
Thiabendazole—Vomiting—Etoposide—urinary bladder cancer	0.00138	0.00206	CcSEcCtD
Thiabendazole—Rash—Etoposide—urinary bladder cancer	0.00136	0.00204	CcSEcCtD
Thiabendazole—Dermatitis—Etoposide—urinary bladder cancer	0.00136	0.00204	CcSEcCtD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00136	0.00409	CbGpPWpGaD
Thiabendazole—Headache—Etoposide—urinary bladder cancer	0.00136	0.00203	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00133	0.00401	CbGpPWpGaD
Thiabendazole—Leukopenia—Epirubicin—urinary bladder cancer	0.00133	0.00199	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00131	0.00396	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.00131	0.00396	CbGpPWpGaD
Thiabendazole—Confusional state—Methotrexate—urinary bladder cancer	0.00131	0.00196	CcSEcCtD
Thiabendazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.0013	0.00194	CcSEcCtD
Thiabendazole—Vision blurred—Doxorubicin—urinary bladder cancer	0.0013	0.00194	CcSEcCtD
Thiabendazole—Convulsion—Epirubicin—urinary bladder cancer	0.00129	0.00193	CcSEcCtD
Thiabendazole—Nausea—Etoposide—urinary bladder cancer	0.00129	0.00192	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.00127	0.00384	CbGpPWpGaD
Thiabendazole—Anorexia—Methotrexate—urinary bladder cancer	0.00124	0.00185	CcSEcCtD
Thiabendazole—Leukopenia—Doxorubicin—urinary bladder cancer	0.00123	0.00184	CcSEcCtD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00123	0.00371	CbGpPWpGaD
Thiabendazole—Confusional state—Epirubicin—urinary bladder cancer	0.00122	0.00183	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00122	0.00367	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00121	0.00181	CcSEcCtD
Thiabendazole—Hypotension—Methotrexate—urinary bladder cancer	0.00121	0.00181	CcSEcCtD
Thiabendazole—Convulsion—Doxorubicin—urinary bladder cancer	0.00119	0.00178	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.00117	0.00352	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.00116	0.0035	CbGpPWpGaD
Thiabendazole—Anorexia—Epirubicin—urinary bladder cancer	0.00116	0.00173	CcSEcCtD
Thiabendazole—Somnolence—Methotrexate—urinary bladder cancer	0.00115	0.00172	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.00115	0.00346	CbGpPWpGaD
Thiabendazole—Dyspepsia—Methotrexate—urinary bladder cancer	0.00114	0.00171	CcSEcCtD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.00114	0.00342	CbGpPWpGaD
Thiabendazole—Hypotension—Epirubicin—urinary bladder cancer	0.00113	0.0017	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—urinary bladder cancer	0.00113	0.00169	CcSEcCtD
Thiabendazole—Decreased appetite—Methotrexate—urinary bladder cancer	0.00113	0.00169	CcSEcCtD
Thiabendazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00112	0.00168	CcSEcCtD
Thiabendazole—Fatigue—Methotrexate—urinary bladder cancer	0.00112	0.00167	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.00109	0.0033	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00109	0.0033	CbGpPWpGaD
Thiabendazole—Somnolence—Epirubicin—urinary bladder cancer	0.00108	0.00161	CcSEcCtD
Thiabendazole—Anorexia—Doxorubicin—urinary bladder cancer	0.00107	0.0016	CcSEcCtD
Thiabendazole—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00107	0.0016	CcSEcCtD
Thiabendazole—Dyspepsia—Epirubicin—urinary bladder cancer	0.00107	0.0016	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.00106	0.0032	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.00106	0.0032	CbGpPWpGaD
Thiabendazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00106	0.00159	CcSEcCtD
Thiabendazole—Decreased appetite—Epirubicin—urinary bladder cancer	0.00105	0.00158	CcSEcCtD
Thiabendazole—Hypotension—Doxorubicin—urinary bladder cancer	0.00105	0.00157	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.00105	0.00316	CbGpPWpGaD
Thiabendazole—Fatigue—Epirubicin—urinary bladder cancer	0.00105	0.00156	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00103	0.00312	CbGpPWpGaD
Thiabendazole—Abdominal pain—Methotrexate—urinary bladder cancer	0.00102	0.00153	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.00102	0.00307	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000999	0.0015	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—urinary bladder cancer	0.000998	0.00149	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000992	0.00148	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000988	0.00148	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000976	0.00146	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—urinary bladder cancer	0.000968	0.00145	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000962	0.0029	CbGpPWpGaD
Thiabendazole—Abdominal pain—Epirubicin—urinary bladder cancer	0.000959	0.00143	CcSEcCtD
Thiabendazole—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000955	0.00143	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000952	0.00287	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000948	0.00286	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000931	0.00281	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000931	0.00281	CbGpPWpGaD
Thiabendazole—Asthenia—Methotrexate—urinary bladder cancer	0.00093	0.00139	CcSEcCtD
Thiabendazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000925	0.00138	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000918	0.00137	CcSEcCtD
Thiabendazole—Pruritus—Methotrexate—urinary bladder cancer	0.000917	0.00137	CcSEcCtD
Thiabendazole—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000894	0.00134	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000887	0.00133	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000887	0.00267	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000887	0.00267	CbGpPWpGaD
Thiabendazole—Diarrhoea—Methotrexate—urinary bladder cancer	0.000887	0.00133	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000884	0.00267	CbGpPWpGaD
Thiabendazole—CYP1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000883	0.00266	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.00088	0.00265	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000871	0.00263	CbGpPWpGaD
Thiabendazole—Asthenia—Epirubicin—urinary bladder cancer	0.00087	0.0013	CcSEcCtD
Thiabendazole—Pruritus—Epirubicin—urinary bladder cancer	0.000858	0.00128	CcSEcCtD
Thiabendazole—Dizziness—Methotrexate—urinary bladder cancer	0.000857	0.00128	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000838	0.00253	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000837	0.00253	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000832	0.00251	CbGpPWpGaD
Thiabendazole—Diarrhoea—Epirubicin—urinary bladder cancer	0.00083	0.00124	CcSEcCtD
Thiabendazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000827	0.00124	CcSEcCtD
Thiabendazole—Vomiting—Methotrexate—urinary bladder cancer	0.000824	0.00123	CcSEcCtD
Thiabendazole—Rash—Methotrexate—urinary bladder cancer	0.000817	0.00122	CcSEcCtD
Thiabendazole—Dermatitis—Methotrexate—urinary bladder cancer	0.000816	0.00122	CcSEcCtD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000814	0.00245	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000812	0.00245	CbGpPWpGaD
Thiabendazole—Headache—Methotrexate—urinary bladder cancer	0.000812	0.00121	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000811	0.00245	CbGpPWpGaD
Thiabendazole—Asthenia—Doxorubicin—urinary bladder cancer	0.000805	0.0012	CcSEcCtD
Thiabendazole—Dizziness—Epirubicin—urinary bladder cancer	0.000802	0.0012	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.0008	0.00241	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000799	0.00241	CbGpPWpGaD
Thiabendazole—Pruritus—Doxorubicin—urinary bladder cancer	0.000794	0.00119	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000784	0.00236	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000782	0.00236	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000782	0.00236	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000777	0.00234	CbGpPWpGaD
Thiabendazole—Vomiting—Epirubicin—urinary bladder cancer	0.000771	0.00115	CcSEcCtD
Thiabendazole—Nausea—Methotrexate—urinary bladder cancer	0.00077	0.00115	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000768	0.00115	CcSEcCtD
Thiabendazole—Rash—Epirubicin—urinary bladder cancer	0.000765	0.00114	CcSEcCtD
Thiabendazole—Dermatitis—Epirubicin—urinary bladder cancer	0.000764	0.00114	CcSEcCtD
Thiabendazole—Headache—Epirubicin—urinary bladder cancer	0.00076	0.00114	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000748	0.00226	CbGpPWpGaD
Thiabendazole—Dizziness—Doxorubicin—urinary bladder cancer	0.000742	0.00111	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000732	0.00221	CbGpPWpGaD
Thiabendazole—Nausea—Epirubicin—urinary bladder cancer	0.00072	0.00108	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—urinary bladder cancer	0.000714	0.00107	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—urinary bladder cancer	0.000708	0.00106	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—urinary bladder cancer	0.000707	0.00106	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—urinary bladder cancer	0.000703	0.00105	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000697	0.0021	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000697	0.0021	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000678	0.00204	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000678	0.00204	CbGpPWpGaD
Thiabendazole—Nausea—Doxorubicin—urinary bladder cancer	0.000667	0.000997	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000607	0.00183	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000605	0.00182	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000594	0.00179	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000594	0.00179	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000566	0.00171	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000566	0.00171	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000563	0.0017	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000561	0.00169	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000561	0.00169	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000555	0.00167	CbGpPWpGaD
Thiabendazole—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	0.000544	0.00164	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000541	0.00163	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000539	0.00162	CbGpPWpGaD
Thiabendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000532	0.00161	CbGpPWpGaD
Thiabendazole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000517	0.00156	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	0.000513	0.00155	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NAT1—urinary bladder cancer	0.000513	0.00155	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00051	0.00154	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000504	0.00152	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000477	0.00144	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000469	0.00141	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000422	0.00127	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	0.000399	0.0012	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	0.000389	0.00117	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000367	0.00111	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000345	0.00104	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000327	0.000986	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000327	0.000986	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000322	0.00097	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000312	0.00094	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—TYMP—urinary bladder cancer	0.000311	0.000937	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	0.000299	0.000902	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000298	0.0009	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NAT2—urinary bladder cancer	0.000281	0.000847	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	0.000269	0.000812	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	0.000254	0.000767	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	0.000248	0.000747	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—RRM2—urinary bladder cancer	0.000243	0.000731	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ENO2—urinary bladder cancer	0.000225	0.000677	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	0.000225	0.000677	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000223	0.000673	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	0.000218	0.000657	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000215	0.000647	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000199	0.000599	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	0.000198	0.000597	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.00019	0.000574	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NQO1—urinary bladder cancer	0.000181	0.000546	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	0.000179	0.00054	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000176	0.00053	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	0.000155	0.000466	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000153	0.000462	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	0.000151	0.000455	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000146	0.000441	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	0.000143	0.000432	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	0.000143	0.000432	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000142	0.000429	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—TYMS—urinary bladder cancer	0.00014	0.000423	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	0.000139	0.000419	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	0.000139	0.000418	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	0.000139	0.000418	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000137	0.000412	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GPX1—urinary bladder cancer	0.000133	0.000401	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	0.00013	0.000393	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	0.000123	0.00037	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	0.000115	0.000348	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000112	0.000338	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PPARG—urinary bladder cancer	9.95e-05	0.0003	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.77e-05	0.000295	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.63e-05	0.00029	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	9.55e-05	0.000288	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.32e-05	0.000281	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.95e-05	0.00027	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.85e-05	0.000267	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.85e-05	0.000267	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	8.47e-05	0.000255	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	8.32e-05	0.000251	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	7.82e-05	0.000236	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.82e-05	0.000236	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTEN—urinary bladder cancer	6.82e-05	0.000206	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—EP300—urinary bladder cancer	6.51e-05	0.000196	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	6.34e-05	0.000191	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.09e-05	0.000184	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.99e-05	0.00015	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.35e-05	0.000131	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.15e-05	0.000125	CbGpPWpGaD
